| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2840-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2810-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70596
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 |
| filingDate |
2014-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-102396589-B1 |
| titleOfInvention |
Rna trnascription vector and uses thereof |
| abstract |
The present invention relates to an improved RNA transcription vector, and is very suitable for preparing mRNA for in vivo therapeutic purposes. This improvement in the vector is due to the presence of translation enhancers (TEs) and nuclear retention sequences (NRSs), particularly when the latter is the "expression and nuclear retention component" (ENE) of Kaposi's sarcoma herpes virus (KSHV). it is by |
| priorityDate |
2013-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |